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Abstract

PHOSPHOLIPASE A, INDUCED MONOCYTE CHEMOTAXIS TO
APOPTOTIC CELLS
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KWASI KARIKARI, B. S.
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Science in Biochemistry at Virginia Commonwealth University.
Virginia Commonwealth University, 2006
Major Director: Suzanne E. Barbour, Ph.D.
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Department of Biochemistry

Apoptosis is a form of programmed cell death that is essential in such processes as
organ and tissue remodeling and maturation of hematopoietic cells. The clearance of
apoptotic cells is essential to prevent autoimmune responses to sequestered antigens. This
process is mediated by phagocytes of the monocyte lineage. Before phagocytosis can
occur, macrophages must be recruited to the apoptotic cells through chemotaxis. Products
of the reaction catalyzed by the phospholipases A2 (PLA2) have been shown to induce
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monocyte chemotaxis either directly or indirectly. Some investigators have implicated a
cytosolic calcium-independent PLA2 (iPLA2)in the production of these products during
apoptosis. However, a recent report suggests that the secreted group IIa (sPLA2)binds to
surfaces of apoptotic cells. The "receptor" for this pool of sPLA2is the rod domain of
vimentin, an intermediate filament protein that is exposed by caspase activity when cells
undergo apoptosis. Based on these observations, we hypothesize that the exposure of
vimentin on apoptotic cells traps a pool of catalytically active sPLA2that then generates
the bioactive lipids that induce macrophage chemotaxis. In our methods, [3~]-oleate
labeled E-coli is used as a substrate for sPLA2 and enzyme activity is quantified by
scintillation counting of released radiolabeled oleic acid. Apoptosis is induced with anti-fas
(CD-95) on Jurkat cells and monitored through annexin-V binding and propidium iodide

(PI) staining followed by flow cytometric analyses. THP-1 monocytes are employed in
chemotaxis assay with monocyte chemotactic protein (MCP- 1) as a positive control. The
preliminary data show equivalent group IIa sPLA2association with anti-fas treated and
control cells, and the enzyme remains catalytically active when bound. In line with the
hypothesis, trapped sPLA2 generated soluble molecules that directly or indirectly induced
migration of THP-1 monocytes. However, the similar binding effect observed with
apoptotic or control cells is surprising and experiments are being planned to determine if
the interaction between IIa sPLA2and apoptotic cells is vimentin dependent.

Introduction
Apoptosis or programmed cell death is an active process which causes typical
morphological and biochemical changes including cell shrinkage, nuclear condensation
and fragmentation, and membrane alterations such as loss of sialic acid residues from
membrane glycoproteins (3). Apoptosis usually affects scattered cells in a tissue and is
triggered by a host of stimuli in both physiological (organ and tissue remodeling and the
development and maturation of hematopoietic cells) and pathological settings. In contrast,
necrosis or passive cell death is a pathological process induced by physical or chemical
stimuli (1 1).
The recognition and removal of apoptotic and necrotic cells by phagocytes
(macrophage and dendritic cells) is mediated by changes in expression of membrane
associated markers on the dying cell and occurs via distinct and non-competitive
mechanisms. Fadok and colleagues identified a phosphatidylserine (PS) receptor on the
surface of activated macrophages that selectively allows the PS dependent uptake of
apoptotic cells, in addition to other receptors such as CD-36, thrombospondin and lectins
(8). Binding of PS to its receptor triggers the release of anti-inflammatory cytokines such
as transforming growth factor-p (TGF-p) and inhibits production of pro-inflammatory
cytokines such as tumor necrosis factor-a (TNF-a), providing a link between the
recognition of apoptotic cells and the physiological consequences of their uptake (6).
Monocyte-derived dendritic cells can engulf apoptotic cells and display the
degraded peptides on their surface via a major histocompatibility complex (MHC). These
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MHC- peptide complexes with the ligands for antigen receptors on T cells which can
thereby regulate T cell activity (6). Uptake of necrotic cells results not only in peptide
presentation on the cell surface but also, activation of the dendntic cells to express costimulatory molecules which are necessary for T cell activation and induction of an
inflammatory response. In contrast, apoptotic cells do not trigger co-stirnulatory molecules
expression and without that, the MHC complexes selectively inactivate the T cell that
recognize them leading to tolerance (Fig 1).

Figure 1: Phagocytes including (macrophages and dendritic cells) can engulf and degrade
both apoptotic and necrotic cells leading to immune activation (a) or tolerance (b). From
Green et a1 (33).
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Before phagocytosis can occur, monocytes must be recruited to the apoptotic cells
through chemotaxis. Products of the reaction catalyzed by the phospholipases A2 (PLA2)
family of heterogeneous enzymes whose common feature is to hydrolyze the fatty acid
esterified at the sn-2 position of glycerophospholipids, have been shown to induce
monocyte chemotaxis either directly or indirectly. Some investigators have implicated a
cytosolic calcium-independent PLA2(iPLA2)in the production of these products during
apoptosis but a recent report suggests that the secreted group IIa (sPLA2)binds to surfaces
of apoptotic cells. The sPLA2are proteins of relatively low molecular mass (14-23 kDa),
highly enriched in disulfide bonds, and require millimolar levels of Ca2+for activity (16).
One "receptor" for this pool of sPLA2 is the rod domain of vimentin which is the most
widely expressed type 111 ~ntermediat-eFilament (IF) protein.
Intermediate filament proteins associate with the nuclear envelope via the tail
domain, and to the plasma membrane via the positively charged head domain. Their
proposed cellular functions are to support the transport of specific population of vesicles
and to maintain organelle structures (4). Consequently, this interaction between vimentin
and group Ila sPLA2gained considerable attention following the initial observations that
autoantibodies from patients with autoimmune diseases could bind apoptotic cells. Gensler
et a1 hypothesized then that posttranslational modification or relocation of some proteins
during apoptosis could be involved in autoimmunity. To test this hypothesis, they injected
apoptotic Jurkat T cells into BALBIc mice and obtained monoclonal antibodies against
vimentin (15). Since vimentin is a known autoantigen -- antivimentin antibodies are found
in the sera of patients with Rheumatoid Arthritis (RA), Myocarditis, and Systemic Lupus
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Erythematosus (SLE) --these studies collectively provoked the possibility of vimentin
externalization during apoptosis (4).
In the early stages of apoptosis, vimentin is partially exposed on the surface of
apoptotic T cells via the action of caspases and binds to group IIa sPLA2in a Ca2+independent manner via its 37 kDa rod domain. Studies with IIa sPLA2mutants with
charge reversal (Lys 11OGldLys1 l5Glu) showed that specific motifs in the interfacial
binding surface are involved in the interaction with vimentin. The IIa sPLA2inhibitor
LY3 11727, but not heparan inhibited this interaction with vimentin (4). In contrast, heparin
but not LY3 11727 abrogated the binding of IIa sPLA2 to cellular heparan sulfate
proteoglycans (HSPG). Importantly, vimentin does not inlubit the catalytic activity of IIa
sPLA2,
Interestingly, vimentin externalization in early apoptosis occurs simultaneously
with PS exposure and chromatin condensation but both are now known to be independent
processes (3). An aminophospholipid translocase flips PS from the outer to the inner
leaflet. Data presented by Fadok et a1 (1) demonstrated that loss of amino-phospholipid
translocase activity alone does not result in PS appearance but more likely, results from a
calcium-dependent phospholipid flip-flop that is non-specific for head group. Nevertheless,
while loss of translocase activity is insufficient to result in PS appearance, loss of its
function is probably a necessary event and the appearance of PS on the cell surface can be
Qssociated from nuclear changes during apoptosis (1). Collectively, PS exposure on the
cell surface then may or may not be sufficient for the binding of IIa sPLA, to apoptotic

human T cells and suggests possibly, a role for binding sites other than anionic
phospholipids on membranes of apoptotic cells.
Hence, the presence of multiple recognition mechanisms suggests that removal of
apoptotic cells is an important function and we are intrigued by the possibility that the
exposure of vimentin on apoptotic cells traps a pool of catalytically active IIa sPLA2that
then generates the bioactive lipids that induce macrophage chemotaxis to the apoptotic
cell. Understanding this process which we propose to be linked in our mechanistic model
(Fig 2) will require clarification of the ways in which the distinct mechanisms interact and
together, these studies should illustrate a novel function of group IIa sPLA2and may
suggest new ways to enhance the clearance of apoptotic cells and thereby prevent
autoimmune responses.

Figure 2: Proposed Model for ~ecruitmentof Macrophages by "trapped" sPLA2.
1. A portion of vimentin is exposed on the surface of the apoptotic cell. 2. This is a
receptor for sPLA, that is then "trapped" on the surface of the apoptotic cell. 3. This pool
of sPLA, is catalytically active and generates bioactive lipids (LPC, LTC,, PGE,) that
induce macrophage chemotaxis to apoptotic cells (either directly or indirectly).
4. Macrophages then phagocytize and clear the apoptotic cells, thereby preventing the
induction of autoimmune responses against sequestered or exposed antigens.

PLA2Family (sPLA2, iPLA2, cPLA2)
Phospholipase A, enzymes can be broadly classified into three major classes on the
basis of their requirements for calcium, the mechanism of their catalytic action, their
molecular weight and also sequence homology (Table 1).
Enzyme
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Table 1: Forms of Phospholipase A, Expressed by Mammalian Cells from Kapur (31)
The secretory enzymes, sPLA, groups I, 11, II,II,II,V,X, and XI1 are all
approximately 14 kDa and all possess a catalytic histidine residue that functions as a
general base to activate a water molecule for hydrolysis of the ester bond (19).
Additionally, a Ca2+ion is required at the active site that functions as a Lewis acid to
polarize the ester carbonyl group and facilitate attack by the water molecule. A second Ca2'
plays a structural role (Fig.3). The requirement for Ca2+at rnM concentrations for activity
suggests that these enzymes do not function intracellularly where Ca2+concentrations
should normally be low in uM ranges (19).
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Also, they possess about 7 disulfide bonds making the enzyme stable but inactive
in acidic medium (Fig 4). The interface of sPLA,s contains a collar of hydrophobic
residues that surrounds the opening to the catalytic site slot and two or more cationic
arginine and lysine residues. As a result of these basic residues, the interfacial binding site
of sPLA,s has a positive electrostatic potential which could explain the hgh affinity of
these enzymes for anionic interfaces and molecules (28). The difference between the
enzymes in this family is the interfacial binding surfaces that modulate their binding
affinity for different kinds of phospholipids. As such, the group IIa preferentially binds
anionic substrates (PS, PE) whilst the group V shows no preference.

Figure 3: Binding surface and mechanism of catalysis by Phospholipase A,. X-ray
structural model of Phospholipase A, showing the surface that interacts with a membrane.
The interfacial binding surface contains a rim of positively charged arginine and lysine
residues surrounding the catalytic active site in whch a substrate lipid is bound (a). After
docking on a model lipid membrane, positively charged polar groups at the interfacial
binding site bind to negatively charged polar groups at the membrane surface. The binding
triggers a conformational change, opening a channel lined with hydrophobic amino acids
that leads from the bilayer to the catalytic site. As a phospholipid moves into the channel,
an enzyme-bound CaZ+ion binds to the head group positioning the ester bond to be cleaved
next to the catalytic site. From Lodish et a1 (17).

Figure 4: Primary structure of Pancreatic sPLA,s. From Haas et a1 (34).
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The cytosolic PLA, enzymes with much larger molecular weights typically 85 kDa,
possess a catalytic serine residue that forms a covalent acyl ester intermediate during
hydrolysis that is subsequently broken down by a water molecule. cPLA, does not require
any Ca2+for catalytic activity, however micromolar concentrations of Ca2+induce a
translocation of the enzyme from the cytoplasm to the cell membrane where it is
functionally active by phosphorylation, suggesting that cPLA2-aisoform is involved in
receptor-mediated activation of cells. These serine esterases lack disulfide bonds and the
three isoforrns cPLA, -a, cPLA, -p, and cPLA, -y are ubiquitously expressed. The
cPLA2-y maybe involved in basal phospholipids metabolism of lower organisms such as
amoeba (32). The cPLA, enzymes do not show a preference for phospholipids with a
particular head group. However, they do prefer substrates containing arachidonic acid in
the sn-2 position.
The iPLA, are calcium-independent and has molecular weight of 80-88 kDa
depending on species and alternative splicing mechanisms, a catalytic serine and no
requirement for Ca2+.These serine esterases are found in the cytosolic compartment and do
not have any disulfide bonds. Like the cPLA,, iPLA, also prefers to hydrolyze the sn-2
position of phospholipids, but can also utilize the sn-1 position. Most studies suggest that
IPLA, is involved in basal lipid metabolism.
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sPLA, and Bioactive Lipids
Phospholipids also contribute to cell physiology by being storehouses for signaling
molecules in addltion to their structural roles. The products of the PLA, reaction,
lysophospholipid and the unesterified fatty acid can be converted into second messengers
that then regulate cell physiology. The lysophospholipid product can be involved in the
production of Platelet-Activating Factor (PAF), a pro-inflammatory lipid that binds to
G- protein-coupled receptors (GPCR) on a variety of cells (35). Lysophospholipids (LPA,
LPC) bind receptors and have been shown to have a variety of effects on cell physiology
(32).
The Lipoxygenase (LOX) and Cycloxygyenase (COX) enzymes can convert
unesterified polyunsaturated fatty acids (PUFA) into oxygenated derivatives (Leukotrienes
and Prostanglandins, respectively), (Fig. 5). Like PAF, these molecules can exert their proinflammatory activities through binding to GPCR (35). Also, Prostaglandin E2(PGE,)
binds receptors on macrophages and dendritic cells and up-regulates the expression of
CCR7, the receptor for chemolnes (CCL19 and CCL21) that are essential for recruitment
into secondary lymphoid tissues (36). Similarly, Leukotrienes (LTC,) is necessary for
optimal chemotactic responses of dendritic cells to CCL19, and LPC is a chemoattractant
for monocytes (7).

Figure 5: (A) Specificity of Phospholipases. Each type of phospholipase cleaves one of
the susceptible bonds represented by the arrows. The phospholipase A, enzyme is specific
for the sn-2 position. (B) sPLA, and lipid metabolism. sPLA, esterase activity on
phosphatidylcholine (PC) generates arachdonic acid (AA) from the the sn-2 position and
lyso-phosphatidylcholine (LPC). Arachidonic acid is subject to downstream COX-2 and
5-LOX enzymes to yield prostaglandings pG&), thromboxanes (TXA,) and
leukotrienes (LTC,) whlch are pro-inflammatory lipid mediators.
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An important connection between sPLA, and signal transduction pathways
emerged from the discovery that some mammalian isoforms including sPLA, IIa bind with
high affinity to receptors first associated with the toxic effect of venom-secreted PLA,
(20). The first sPLA,-binding protein is most abundant in brain and named N-type
(neuronal type) receptor. The second type of receptor for sPLA, IIa was initially found in
skeletal muscle and termed the M-type (muscle type) receptor (29). The M-type has been
characterized as a member of a family of transmembrane proteins with similar structural
organization to the C-type multilectin macrophage mannose receptor. A common function
of this protein family is endocytosis and it has been proposed that the physiological role of
the M-type sPLA, receptor is to internalize and deliver sPLA, IIa to specific compartments
within the cell where the enzyme might exert its activity (26). Interestingly, the M-type
sPLA, has been proposed as the main mechanism of action explaining the effects of sPLA,
in macrophages and mast cells (18). Unlike the mouse sPLA, IIa, human sPLA, IIa has not
been found to bind to the M-type receptor thus making it likely that not all of the
physiological receptors for sPLA, have been characterized as yet (20).

Hypothesis
If exposure of vimentin on apoptotic cells traps a pool of catalytically active
sPLA2, then the bioactive lipids generated can induce monocyte/macrophage chemotaxis.

Materials and Methods
Materials: Jurkat clone E6-1 and THP-1 cells were obtained from ATCC (Manassas,

VA). Recombinant Human CCL2LMCP-1 was obtained from R&D Systems. Vybrant
Apoptosis Assay Kit used for flow cytometric analysis was obtained from Molecular
Probes. Para-bromphenacylbromide (BPB) was purchased from Sigma-Aldrich.

Cell Culture: Jurkat cells were maintained in Modified RPMI-1640 medium (ATCC)

supplemented with 100ug/mL penicillin and 100ugImL streptomycin, at 7.5% CO,, 100%
humidity and 37" C. THP- 1 monocytes were cultured at lo6cells1mL in RPMI- 1640
medium supplemented with 10% heat inactivated fetal calf serum, 100ug/mL penicillin
and 100ugImL streptomycin, and also 2 rnM L-glutamine at 7.5% CO,, 100% humidity and
37°C. Cell viability was determined by Trypan Blue dye exclusion with a hemacytometer.
Cell viability exceeded 94% in all experiments.

Group IIa sPLA2Plasmid Transfection: Mammalian expression vector encoQng human

group IIa sPLA, was obtained from Dr. Mike Gelb (University of Washington). Human
Embryonic Kidney (HEK) cells were transiently transfected with the IIa plasmid to overexpress the enzyme by utilizing the FuGENE 6 Transfection protocol (Roche). After 24
hours of incubation at 7.5% CO,, 100% humidity and 37"C, harvested cultured supernatant
was used as source of group IIa sPLA,.

26
Induction ofApoptosis: Fas-mediated apoptosis was induced by adding 20 ng/mL CD95

(AntiFas, BD Pharrningen) to 1x106cells/mL cultured Jurkat cells. Cells were then
incubated in 7.5% CO,, 100% humidity at 37°C for desired time point (4,12,&18 hrs), and
apoptosis was monitored through annexin-V binding and PI staining followed by flow
cytometric analysis.

Acid Extraction of Group Ira Secreted P U 2 : After apoptotic induction, Jurkat cells

(lo6cells/mL) were resuspended in PBS. Twenty-five micro-liters (25 uL) of group IIa
sPLA2 was added on ice to equal amount of cells for both treatment and control samples.
Samples were then incubated on ice for 30 mins and then centrifuged at 5000 x g for 20
mins. Cell pellets were saved and washed in 3 mL PBS. Finally, cells were re-suspended in
750 uL of 0.36N sulfuric acid and left overnight at 4°C. After 20 mins of centrifugation the
next morning, the supernatant containing soluble proteins were removed for assay and
stored at 4°C. Protein concentration was then determined using the Lowry BSA method.
The acid extraction protocol denatures all proteins except the group IIa enzyme which
remains stable but inactive in acidic medium.

Activity Assay: Group IIa sPLA, activity was measured using radiolabeled E. coli cells as

a substrate. [3H] Oleic acid-labeled E. coli membranes were prepared by standard
procedures (16). Equivalent amounts of acid extracted enzyme (0.4 or 1.0 ug) or cultured

-

supernatants (50 uL) were incubated with 50,000 cpm of E. coli cells in sPLA, assay
buffer ( 25 mM Tris-base, pH 9.0, 10 mM calcium chloride, 5 mg/mL fatty acid-free
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bovine serum albumin (FAF-BSA)) in a final volume of 500 uL for 20 mins at 37°C. The
reaction was stopped by the addition of 250 uL 2N HCl and liberated fatty acids were
extracted by adding 250 uL of 20 mg/mL FAF-BSA. After 20 mins incubation on ice, the
reaction mixture was centrifuged at 7000 x g and 500 uL of supernatant was used for
scintillation counting. The percent hydrolysis is determined by the percent of input counts
released into supernatants.

Flow Cytometric Analysis of Cell Size and Viability: Cells were pelleted, washed 2X in

PBS and resuspended in 1X Binding Buffer (1XBB: 0.0 1 M Hepes/NaOH (pH 7.4) 0.14 M
NaC1,2.5 mM CaCl,) at a concentration of 106cells/mL. Five micro-liters (5 uL) each of
10 ug/mL Propidium Iodide (PI, sigma) and Annexin-FITC were added to 100 uL of cells
in 1X Binding Buffer, and incubated at room temperature for 15 mins. Samples were then
transferred to ice, volume brought to 0.5 mL with 1X Binding Buffer and analyzed on a
BD FACSCAN flow cytometer . The distribution of cell size and density is represented by
forward scatter versus side scatter dot plots respectively and gates were set based on
control samples to distinguish normal and shrunken cells. Annexin-FITC positive cells
were determined as described in the Vybrant Apoptosis Assay kit by setting quadrants to
separate viable cells from PI permeant cells, and non-apoptotic cells from those staining
highly for the Annexin probe. Percent quadrant cell population was determined by
statistical analysis of gated region using CellQuest and WinMDI 2.8 softwares.
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Transmigration Assay and Production of Candidate Chemoattractant Cell Supernatants:

After induction of apoptosis, cells were resuspended in 100 uL of PBS (9.4 uL of 1M
CaCI2/3 mL PBS) per 100,000 cells on ice. Twenty-five micro-liters (25 uL) of group IIa
sPLA, was added and incubated for 30 mins on ice, followed by 20 mins in a 37°C water
bath with the shaker at moderate speed. Cells were then centrifuged at 10,000 x g for 5
mins and supernatants used in chemotaxis assay. Transmigration assays were performed
using 8um pore size Transwell plates (Fisher). One hundred micro-liters (100 uL) of
chemoattractant or supernantants from treated or non-treated cells described above were
added to 500 uL of 2% FCS medium and placed into the lower chamber. Also, lo5THP-1
monocytes were added to the upper chamber and the assay was incubated for 2 hrs at 37°C.
Migrated and non-migrated monocy& were determined utilizing a BD Coulter Counter
and transmigration was assessed as percent of total cells recovered in lower chamber.
Para-bromophenacylbromide (BPB) Inactivation of IIa sPLA,: Group IIa sPLA2was

dialyzed with PBS for 16 hours using 3.5K dialysis tubing. Four hundred microliters of
dialyzed enzyme was incubated with 10 uL BPB (200 mM in Methanol) on ice for 30
minutes and tested for catalytic activity.

Statistical Analysis: Data shown are mean and standard deviation of a single representative

experiment done in triplicate. Statistical significance was determined by using the
student's t-test with p< 0.05.

Results
Cultured supernatant containing group IIa sPLA2 shows phospholpase activity: The

source of IIa sPLazfor these studies was a cultured supernatant from transiently transfected
HEK cells in serum free medium as described in methods. Quantification of IIa sPLA,
activity shows a remarkable seventeen fold hydrolysis compared to control (Fig 6).

Figure 6: Cultured supernatant containing group IIa sPLA, shows phospholipase
activity. HEK cells were transiently transfected with group IIa sPLA, vector plasmids or
control in serum-free DME medium. Cultured supernatants were harvested after 24 hrs and
activity quantified as percent hydrolysis by scintillation counting of released radiolabeled
oleic acid.

group Ila

Control
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Forward scatter (FSC), Side scatter (SSC), AnnexinV-FITC, and Propidium Iodide (PI)
staining indicates cells are undergoing apoptosis induced by anti-fas: To induce

apoptosis, Jurkat cells (106/mL)were added to 20 ng/mL anti-fas and incubated for desired
time-point. Cells were then stained and analyzed by flow cytometry. The forward-angle
light scatter (FSC) relates to the cell diameter and the side-angle light scatter reflects the
density of inner cellular structures (10). During the initial stages of apoptosis, the cell
shrinks while the membrane remains intact. During necrosis, cell swelling occurs as a
result of the early failure of the membrane integrity. As a consequence of these cellular
changes, the FSC decreases during the initial phases of apoptosis while SSC increases or
remains unchanged (6). After some hours, decrease in both FSC and SSC becomes evident
(Fig 7). Taking into consideration that trypan blue positive cells are rather dead cells that
have passed the early apoptotic stage, this observation nevertheless correlated with the
percent cell viability calculations as assessed by trypan blue exclusion for the 24 hr time
course with 20 ng/mL anti-fas treatment (Fig 8). At 0 hr, trypan blue dye exclusion showed
cells were about 95% viable. Control cells fluctuated in that range to 92% viability at 30
hrs. In contrast, the anti-fas treated cells gradually decreased to 4 1.3% viability at 30 hrs.

Figure 7: Transition of Cell Population from Viable to Apoptotic and/or Necrotic by
Forward and Side Scatter Analysis. Flow cytometry for 24hr time course of 20 ng/mL
AntiFas treated cells (&-bottom row) and non-treated cells (&-top row). The distribution
of cell size is represented by forward scatter (vital cells in R1) and side scatter
(apoptotic/necroticcells in R2) dot plots. The percentage of control R2 cell population was
4.9, 11.8, 10.0, and 11.1 for the 4, 8, 10, and 12 hour time-point respectively. The
percentage of anti-fas treated R2 cell population was 10.4, 19.1, 19.3, and 17.5 for the 4, 8,
10, and 12 hour time-point respectively. For the second experimental batch, the percentage
of control R2 cell population was 3.7,6.2,6.5, and 10.0 for the 14, 16,20, and 24 hour
time-point respectively. For the second experimental batch, the percentage of anti-fas
treated R2 cell population was 8.5,22.0,24.2, and 3 1.1 for the 14, 16,20, and 24 hour
time-point respectively.
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Figure 8: Effect of 20 ng/mL ~ n t i - g a treatment
s
on Jurkat cells Viability.
Jurkat cells (1xlO6/mL)were induced to undergo apoptosis by addition of 20 ng/mL
AntiFas. Cell viability at each time point was determined by Trypan Blue dye exclusion
method.
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In Figures 9, 10, and 11, we used annexinv-FITC staining to discriminate between
apoptotic and non-apoptotic cells for the different time-points. In a Ca2+-dependentmanner,
annexinv-FITC binds preferentially to anionic lipid species such as phosphatidylserine
(PS) which is normally absent in the outer leaflet of the plasma membrane, and shows
minimal binding to other phospholipids species such as phosphatidylcholine (PC) which is
constitutively present in the outer leaflet of the plasma membrane. When apoptosis occurs,
PS is translocated to the outer leaflet of the membrane and this is observed in the early
phase of apoptosis.
Consequently, the annexinv-FITC binding assay was combined with propidium
iodide (PI), a vital dye exclusion test in order to collect information about membrane
intergrity which fails early during necrosis whilst remaining intact during the initial phase
of apoptosis (9). Compared to control, the 12 hr time point sample showed about a 3.4 fold
in early apoptotic (LR) cell population (13% vs 4%).We concentrated on the 12 hr time
point because our data consistently showed a higher ratio of early apoptotic cell population
(annexin-V (+), PI (-)) compared to control cells from other time points (Figs 9,10,11).
Moreover, the 12 hour data showed the least ratio of late apoptotic or dead cells (UR:19%)
per early apoptotic cell population (LR: 13%). Additionally, it is noteworthy that the
minimal percentage of non-apoptotic dead cells in UL (1.14%) indicates that the dead cells
seen in UR (19.02%) were cells that transitioned through the apoptotic process since they
showed binding to annexinv-FITC. Quantitatively, the data show a decline in viable cell
population in anti-fas treated group from 78% (4hr) to 67% (12hr) to 56% (18hr). In
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contrast, viable cell population in control group remained unchanged at 9 1% (4hr), 91%
(12hr), and 92% (18hr).

Figure 9: Propidium Iodide (PI) and Annexin-V FITC staining differentiates cell
population into viable (LL), early apoptotic (LR), late apoptotic (UR), and
necrotic (UL). 'LE: PI (+), AnnexinV-FITC (-); LR : PI (+), AnnexinV-FITC (+)
LL : PI (-), Annexin V-FITC (-); LR : PI (-), Annexin V-FITC (+). Data represents
4 hr time-point.
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Figure 10: Propidium Iodide (PI) and Annexin-V FITC staining differentiates cell
population into viable (LL), early apoptotic (LR), late apoptotic (UR), and
necrotic (UL). UL : PI (+), AnnexinV-FITC (-); UR : PI (+), AnnexinV-FITC (+)
LL : PI (-), Annexin V-FITC (-); LR : PI (-), Annexin V-FITC (+). Data represents
12 hr time-point.
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Figure 11: Propidium Iodide (PI) and Annexin-V FITC staining differentiates cell
population into viable (LL), early apoptotic (LR), late apoptotic (UR), and
necrotic (r,TL). UL : PI (+), AnnexinV-FITC (-); UR : PI (+), AnnexinV-FITC (+)
LL : PI (-), Annexin V-FITC (-); LR : PI (-), Annexin V-FITC (+). Data represents
18 hr time-point.
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Group IIa sPLAz associates with apoptotic cells and bound enzyme remains catalytically
active: Having established conditions to generate apoptotic cells, we next determined the

association of group IIa sPLA, with Jurkat cells. Surprisingly, our results in Fig 12 are not
in accord with other findings that anti-fas stimulation results in an increase binding of IIa
sPLA, to apoptotic T cells (2). In the first part of this assay, we allowed ~ ~ c i e n t
interaction between group IIa enzyme exposed to equal populations of anti-fas treated or
control cells without activating its phospholipase activity by keeping samples on ice,
without any source of calcium in the preparation. The 12 hr flow cytometry data (Fig 10)
indicated a 3-fold increase (13% vs 4%) in the number of apoptotic cells in antifas- treated
compared to control populations. Additionally, total annexin-FITC positive cell population
showed a time-dependent increase from 21%, to 32%, to 43% for the 4 hr, 12 hr, and 18 hr
time-points respectively. On the contrary, group IIa sPLA,- cell bound extracts from all
three time-points showed similar activity between anti-fas treated and control groups that
was not statistically different. We expected the anti-fas treated cells to bind more to the
enzyme based on the observation by Boilard et a1 that exposed rod domain of vimentin was
a docking site for group IIa enzyme (4). However, the use of primary human cells in
Boilard's experiment stands in contrast to our Jurkat cell line.Yet, the results provoke the
idea that group IIa interaction with apoptotic cells may be vimentin-independent since
viable cells do not expose the intermediate filament protein.

Figure 12: Equivalent group JIa SPLA, association with control and anti-fas treated
cells and bound enzyme remains catalytically active. Control and anti-fas-treated Jurkat
cells harvested at 4, 12, and 18 hrs were added to 25 uL of cultured IIa sPLA, and
processed for acid extraction as described in methods. Following protein concentration
determination by the Lowry BSA method, 1.0 or 0.4 ug of soluble protein was then used to
quantify the activity of the enzyme. (C+)= control+IIa, (C-)= control, (F-)= anti-fas, and
(F+)= anti-fas+IIa.
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Group IIa sPLA2generates soluble molecules that induce THP-I Monocyte chemotaxis
directly or indirectly to apoptotic cells: Monocyte Chemotactic Protein-1 (MCP- 1) is a

potent P-chemolune that recruits monocytes and promotes cell adhesion and transmigration
across an endothelia layer into tissues via a PKC signaling pathway (13). In Fig 13, we
used the MCP-1 as a positive control to compare potency of the group IIa sPLA, products
as chemoattractants. Supernatants of anti-fas (F+) and expectedly, of control (C+) cells
treated with IIa sPLA, contained a chemotactic factor which was equally as effective as
MCP- 1 in recruiting THP- 1 monocytes. On the other hand, supernatant of anti-fas treated
cells without group IIa sPLA, treatment (F-) minimally affected transmigration of
monocytes and was about 50% less compared to MCP-1. Also, group IIa sPLA, (IIa only)
had no effect on chemotaxis.

Figure 13: Group IIa sPLA, generates soluble bioactive molecules which induce THP1 monocyte chemotaxis directly or indirectly. Control and antifas-treated Jurkat cells
were harvested at 12hrs and processed to obtain cell supernatants for chemotaxis as
described in methods. Six hundred microliters of 10 nM MCP-1 prepared in 2% FCS
RPMI 1640 medium, and 100 uL of possible chemoattractant for samples IIa only, F-,F+,
and C+ was added to 500 uL of 2% FCS RPMI 1640 medium and placed in lower
chamber of transwells. All samples received 100,000 THP-1 monocytes in upper chamber.
(+)= with IIa, (-)=without IIa.

Ila only
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BPB treated sPLAz is no longer active: Group IIa sPLA2can generate chemotactic lipids

directly through catalysis or indirectly through binding to receptors followed by activation
of other phospholipases. To determine whether group IIa sPLA2catalytic activity is
necessary to augment monocyte chemotaxis, the enzyme was treated with parabromophenacylbromide (BPB), an irreversible inhibitor of IIa sPLA, that does not affect
other forms of PLA, (34). The activity assay of BPB-treated sPLA, showed the enzyme
was inhibited (Fig 14). Consequently, the next step in our experimental design is to test the
effect of the catalytically inhibited group IIa sPLA2 on monocyte chemotaxis.

Figure 14: BPB treated sPLA, is no-longer active. Dialyzed group IIa supernatants
(400 uL) is treated with 10 uL of BPB (200 rnM para-bromophenacylbromide dissolved in
methanol). After 30 minutes incubation on ice, inhibitor treated (BPB+IIa) and active IIa
enzymes were tested for catalytic activity in a radiolabeled assay as described in methods.

Ila

Discussion
In this work, we have studied the involvement of secretory type IIa phospholipase
in the signaling cascade that leads to the recruitment of monocytes to apoptotic cells.
Induction of apoptosis in Jurkat cells with 20 ng/mL antifas and subsequent analyses with
trypan blue dye showed the gradual decline of treated cells from 95% to about 4 1%
viability at 30 hours post-treatment. T h s observation correlated with the forward by side
scatter dot plot analysis (Fig 7), and we were convinced that cells were undergoing
apoptosis. To differentiate between early and late apoptotic, as well as necrotic cells
populations, we utilized annexinv-FITC and propidium iodide staining technique.
Consequently, we identified a more than three-fold increase in the ratio of early apoptotic
cells in treatment group compared to control at the 12 hour time point (Fig 10).
Using transiently transfected HEK cells to overexpress the IIa sPLA2,we
determined a robust activity (seventeen fold hydrolysis) of the cultured supernatant with
[3H]-oleateE. coli as a substrate. Upon addition of group IIa sPLA2to treated and control
cells, the IIa sPLA2activity assays showed that the enzyme associates equivalently with
botli cell populations for the different time points (4,12,&18 hrs). This was unexpected
because the flow data showed a time-dependent increase in total annexin-FITC binding to
treated but not control cells. Since the annexin-FITC probe is specific for
phosphatidylserine binding, we were unequivocally convinced that treated cells were
transitioning through stages of apoptotis and the early part of that process results in the
exposure of vimentin to the cell surface. Further analysis of chemotactic activity using
supernatants again showed that the IIa sPLA, generated similar bioactive chemoattractant

molecules when bound to control or treated cells. On the other hand, neither supernatants
from non-IIa sPLA2treated apoptotic cells nor cultured IIa sPLAzalone could induce any
significant level of THP-1 monocyte migration compared to the potent chemokine, MCP-1.
Upon treatment with para-bromophenacyl bromide, the catalytic activity of sPLA2IIa was
completely abolished.
Collectively, our results challenges previous data about the involvement of
vimentin in group IIa sPLA2interactions with apoptotic cells. Boilard et a1 had reported
that vimentin, an intermediate filament and part of the cell's cytoskeleton, is exposed to the
extra-cellular surface by caspase activity early in apoptosis to which the group IIa sPLA2
then binds. Our observation that the exogeneous IIa sPLA2enzyme bound equivalently to
control and treated (apoptotic) cells, even though the early apoptotic cell population in
treated sample was three-fold more, suggests that the enzyme may be binding through
other means. Also, it is worth mentioning that Boilard's experiments involved human
primary cells whilst we used a cultured cell line.
Data presented by Murakami et a1 (18) and others suggest an alternative mechanism
for the IIa sPLA2association with cells through Heparan Sulfate Proteoglycans (HSPG).
The cell surface HSPGs fall into two families of molecules that differ in their core protein
domain structures, the integral syndecans and GPI-anchored glypican (23). The syndecans
have core proteins with a transmembrane and cytoplasmic domain and they possess
heparan sulfate chains near the N-terminus distal to the plasma membrane (27). By
contrast, the glypicans lack a membrane spanning domain, are anchored to the external
surface of the plasma membrane via glycosylphosphatidylinositol (GPI) and have three
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heparan sulfate chains near the C-terminus which are close to the plasma membrane (30).
These sulfated glycosaminoglycans contain fixed anionic sites that confer an overall
electronegative charge to their structures depending on the cell type (36). Practically, the
group IIa sPLA2(with clusters of positively charged lysines and arginines, Fig 4) binds to
HSPG via the anionic glycosaminoglycan moiety (2 1).
Structurally, GPI-anchored proteins generally occur in plasma membrane microdomains like caveolae and lipid rafts that contain intermediate filament proteins including
vimentin (14,22). Previously, glypican 1 has been shown to recruit IIa sPLA2into
caveolae-like compartments of cells. Dynamic changes occur in the subcellular distribution
of glypican which moves to the nucleus and punctate caveolae-like domain, dependmg
upon the activation state of the cell (25). Caveolae form a unique endocytic compartment
at the surface of most cells, are capable of importing molecules and delivering them to
specific locations within the cell as well as compartmentalizinga variety of signaling
activities (24). By means of this caveolae-mediated endocytic event, bound sPLA, IIa can
be translocated to the perinuclear compartments in proximity to COX-2 (22). Also, since
caveolae are a site of Ca2+storage and entry into the cell, sPLA, present inside caveolae
signalsomes may retain enzyme activity even after internalization and translocation to the
perinuclear domain. Although it is not known whether vimentin and HSPGs co-localize in
these membrane micro-domains, these proteins may play a role in the sequestering and
distribution of IIa sPLA2in apoptotic cells.
Additionally, the binding of group IIa sPLA2to heparan sulfate chains of glypican
facilitates its presentation to the putative sPLA2IIa receptor, which transduces signals

leading to increased COX-2 expression (18). In accord with this hypothesis, COX-2
induction by sPLA2IIa in rat serosal mast cells appears to involve a receptor-mediator
pathway (18,23). This type of receptor system utilizing both HSPG and a signal
transducing receptor subunit has been shown for the FGF receptor system in which the
ligand, its tyrosine kinase receptor and HSPG form a stable complex on the cell surface
(18) On the other hand, in hematopoetic cells such as platelets and mast cells, sPLA2IIa is

stored in secretory granules rather than binding to cell surface HSPG (18). Hence, the
implication is that subcellular distribution of sPLA, IIa varies accorQng to cell type and
HSPG molecular species.
Furthermore, results from the chemotaxis assay suggest that the group IIa enzyme
generates soluble bioactive molecules'that induce monocyte chemotaxis directly or
indirectly. Since the mechanism by which group IIa sPLA2specifically generates
chemoattractant molecules from cellular phospholipids after interacting with HSPG is not
clear, it is possible instead that the cytosolic calcium-independent PLA, (iPLA2-VIA),can
be partly responsible for generating the chemoattractant. Evidence presented by Lauber et
a1 (7) that apoptotic cells generate chemotactic factors due to caspase-3 mediated activation
of iPLA2that stimulate the attraction of monocytes support this idea. However, iPLA2
activity was not determined and the evidence remains inconclusive. Hence, to determine if
catalytic activity of group IIa sPLA2is required for monocyte recruitment, we used the
para-bromophenacyl bromide (BPB) to inhibit the enzyme. BPB irreversibly inhibits IIa
sPLA2by alkylating the imidazole side chain on histidme-53 at the active site (34). The
results show a complete abolishment of activity (fig 15). Consequently, the next step in our
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experimental design is to test the effect of the catalytically inhibited group IIa sPLA, on
monocyte chemotaxis.
Additionally, Atsumi et a1 (14) provided convincing evidence that the perturbed
membrane asymmetry of cells undergoing apoptosis enables the access of sPLA,. This
validates our speculation that group IIa sPLA, might contributeto the generation of LPC
via the hydrolysis of PC from the outer leaflet of apoptotic cells (Fig 13). Moreover, our
model Jurkat cells are known to contain about 40% PC (3 1) in the outer leaflet of their
plasma membrane and we are almost certain that in future experiments, LPC would be
identified as the major chemo-attractant in the supernatants. In this experiment, we provide
evidence to support the observation that group IIa sPLA, might also contribute to the
generation of LPC via hydrolysis of phosphatidylcholine (PC) from the outer leaflet of
apoptotic Jurkat cells. T h s would confirm the results in Lauber et a1 which concluded that
only LPC was able to attract THP-1 cells and maximal chemotactic activity of LPC was
observed at a concentration of 20 to 30 uM, whereas higher concentrations reduced the
migration activity of THP-1 cells (7).
In summary, we have provided experimental evidence from this study that
recruitment of macrophage to sPLA, -bound control and apoptotic cells is an
indiscriminatory process. T h s is an important step before the timely removal of apoptotic
cells to prevent the release of toxic and immunogenic intracellular contents into the
surrounding tissue (37). The mechanism involved in recognition and removal has been
studied extensively over the past decade and a number of receptors that mediate the
process have been identified (Fig 15). Based on previous studies (1,8,9) and data from this
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experiment, we also conclude that PS exposure is a separate and unrelated event to IIa

sPLA2binding to apoptotic cells. Hence, once the macrophages are indscriminately
recruited to the source of the chemotactic molecules, then the decision is made as to which
cells are to be phagocytosed based on the diverse and many apoptotic cell recognition
mechanisms such as the PS receptor, mannose receptor or the lectin receptors expressed on
the macrophage (Fig 15).

Figure 15: The phagocyte recognition array in the mammalian clearance of apoptotic cells.
From Fadok et a1 (6).
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Finally, in our future studies, we will establish vimentin-negative Jurkat cells using
siRNA techniques and determine whether vimentin directly impacts on group IIa sPLA,
hydrolysis of cellular phospholipids as well as the ability to generate chemotactic factors.
Also, based on our revised hypothesis (Fig 16) that group IIa sPLA, binds to cells
indiscriminately by interacting with glypican 1 or other HSPGs, we will elucidate the
effect of heparin, a competitive inhibitor of group IIa sPLA, on enzyme binding and ability
to generate chemotactic factors.

Figure 16: Revised model for "trapped sPLA? recruitment of monocytes.
Secreted phospholipase A, is captured by the heparan sulfate chains of a HSPG and thus
accumulates on the plasma membrane from which the enzyme liberates arachidonic acid.
Downstream COX and LOX enzymes utilize the arachdonic acid to generate several proinflammatory lipid mediators, some of which are potential chemoattractants that induces
monocyte chemotaxis to the site of chemoattractant. Once macrophages reach the source of
chemotactic molecules, the decision is made as to which cells are to be phagocytosed
based on the diverse and many apoptotic cell recognition mechanisms.

heparin sulfate
pmteoglymn 1
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Figure 17: Comparison of cell viability by trypan blue exclusion method versus
forward scatter by side scatter analysis using flow cytometry.

VITA
Kwasi KariKari was born on April 26, 1970 in Accra, Ghana. He immigrated to the
United States as a teenager and graduated from Erasmus Hall High, Brooklyn, NY in 1989.
He became a naturalized U.S. Citizen in 1996 while living in Virginia and received a
Bachelor of Science in Chemistry from George Mason University, Fairfax, VA in 1998.
Subsequently, he obtained a Collegiate Professional Teachers License from the State of
Virginia and taught chemistry and physics in Prince William County Schools before
enrolling in graduate school at Virginia Commonwealth University (VCU) in 2004. As a
graduate student, he was inducted into the Phi Kappa Phi Honor Society and also
recognized with an award for "Excellence in Biochemistry" by the Biochemistry
Department. Additionally, he was initially awarded a "Pre-Medical Basic Health Science
Certificate" in Biochemistry and then joined the laboratory of Dr. Suzanne Barbour in May
2005. He completed his research thesis for the Masters of Science in Biochemistry degree
in the summer of 2006 and continued on to Michigan State University College of Human
Medicine for medical studies.

